NASDAQ: MDWDMediwound Ltd Stock
$14.19-0.11 (-0.77%)
Updated Aug 5, 2026
MDWD Price
$14.19
Fair Value Price
N/A
Market Cap
$182.68M
52 Week Low
$13.54
52 Week High
$20.30
P/E
-6.25x
P/B
4.41x
P/S
14.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.48M
Earnings
-$26.11M
Gross Margin
19.6%
Operating Margin
-169.43%
Profit Margin
-180.3%
Debt to Equity
0.93
Operating Cash Flow
-$19M
Beta
0.74
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MDWD Overview
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDWD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MDWD
Ranked#278 of 465
Ranked#278 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.75 | A | |
| $110.69 | A | |
| $8.11 | A |
Be the first to know about important MDWD news, forecast changes, insider trades & much more!
MDWD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDWD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MDWD is good value based on its book value relative to its share price (4.41x), compared to the US Biotechnology industry average (5.31x)
P/B vs Industry Valuation
MDWD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MDWD due diligence checks available for Premium users.
Valuation
MDWD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.25x
Industry
14.89x
Market
14.23x
MDWD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.41x
Industry
5.31x
MDWD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDWD's financial health
Profit margin
Revenue
$1.5M
Net Income
-$3.0M
Profit Margin
-200.1%
MDWD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MDWD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$80.0M
Liabilities
$38.6M
Debt to equity
0.93
MDWD's short-term assets ($52.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDWD's short-term assets ($52.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDWD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MDWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.8M
Investing
$17.8M
Financing
-$421.0k
MDWD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDWD vs Biotech Stocks
Mediwound Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.